Table 2. Univariate and multivariate analysis for response to second platinum-based chemotherapy.
| Variable | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| RR (%) | p-value | OR | 95% CI | p-value | |
| Age (yr) | 0.915 | ||||
| ≤50 | 19.0 | - | - | - | |
| >50 | 17.9 | - | - | - | |
| Histology | 0.845 | ||||
| Squamous cell carcinoma | 17.6 | - | - | - | |
| Adenocarcinoma/adenosquamous cell carcinoma | 20.0 | - | - | - | |
| Stage at initial diagnosis | 0.081 | ||||
| I-II | 30.0 | 1 | - | - | |
| III-IV | 10.3 | 0.42 | 0.07-2.33 | 0.323 | |
| Second-line chemotherapy | 0.868 | ||||
| CDDP based | 17.4 | - | - | - | |
| CDDP analogue based | 19.2 | - | - | - | |
| Prior radiotherapy | 0.026 | ||||
| Yes | 15.2 | 1 | |||
| No | 66.7 | 8.47 | 0.50-142.92 | 0.138 | |
| Pelvic disease | 0.440 | ||||
| Yes | 13.6 | - | - | - | |
| No | 22.2 | - | - | - | |
| Tumor diameter (mm) | 0.318 | ||||
| <30 | 22.6 | - | - | - | |
| ≥30 | 11.1 | - | - | - | |
| PFI<6months | 0.924 | ||||
| Yes | 17.6 | - | - | - | |
| No | 18.8 | - | - | - | |
| PFI<12months | 0.047 | ||||
| Yes | 11.4 | 1 | - | - | |
| No | 35.7 | 4.58 | 0.88-23.81 | 0.070 | |
CDDP, cisplatin; CI, confidence interval; OR, odds ratio; PFI, platinum free interval; RR, response rate.